Real estimates of mortality following COVID-19 infection

Baud, David; Qi, Xiaolong; Nielsen‐Saines, Karin; Musso, Didier; Pomar, Léo; Favre, Guillaume

doi:10.1016/s1473-3099(20)30195-x

Cited by 1,216 publications

(1,144 citation statements)

References 3 publications

Supporting

Mentioning

1,049

Contrasting

Unclassified

Order By: Relevance

“…More than 100,000 people have died worldwide in the COVID-19 pandemic as of April 10, 2020 according to recent data from Johns Hopkins University [16]. As of April 11, 2020, almost 1.7 million people worldwide have been infected [17] with global mortality rates over time leveling off to a higher rate of 5.7% converging with current WHO estimates [18]. These statistics reveal that we may have underestimated the potential threat of COVID-19, and that rapid, effective testing strategies and treatments are essential, especially among those with severe respiratory complications and acute respiratory distress syndrome (ARDS).…”

Section: Introductionmentioning

confidence: 99%

Efficacy of glutathione therapy in relieving dyspnea associated with COVID-19 pneumonia: A report of 2 cases

Horowitz¹,

Freeman²,

Bruzzese

2020

Respiratory Medicine Case Reports

165

156

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Efficacy of glutathione therapy in relieving dyspnea associated with COVID-19 pneumonia: A report of 2 cases

Horowitz¹,

Freeman²,

Bruzzese

2020

Respiratory Medicine Case Reports

165

156

View full text Add to dashboard Cite

“…Although comparative analyses suggest that genomic variability between different isolates of SARS-CoV-2 is generally low (Lu et al, 2020, Zhang e t al, 2020, Tang et al, 2020, the fact that distinct viral episomes show a highly biased geographic distribution is potentially alarming, as, at present, it is not completely clear whether frequent variants reflect the adaptive processes, which result in the emergence of novel, and potentially more virulent strains. Moreover at present it is unclear whether the genomic variability of major clades of SARS-CoV-2 and their biased geographic distribution, could explain -at least in part-apparent differing rates of lethality observed worldwide (Baud et al 2020).…”

Section: Introductionmentioning

confidence: 99%

Comparative genomics suggests limited variability and similar evolutionary patterns between major clades of SARS-CoV-2

Chiara

Horner

Gissi

et al. 2020

Preprint

View full text Add to dashboard Cite

Phylogenomic analysis of SARS-CoV-2 as available from publicly available repositories suggests the presence of 3 prevalent groups of viral episomes (super-clades), which are mostly associated with outbreaks in distinct geographic locations (China, USA and Europe). While levels of genomic variability between SARS-CoV-2 isolates are limited, to our knowledge, it is not clear whether the observed patterns of variability in viral super-clades reflect ongoing adaptation of SARS-CoV-2, or merely genetic drift and founder effects. Here, we analyze more than 1100 complete, high quality SARS-CoV-2 genome sequences, and provide evidence for the absence of distinct evolutionary patterns/signatures in the genomes of the currently known major clades of SARS-CoV-2. Our analyses suggest that the presence of distinct viral episomes at different geographic locations are consistent with founder effects, coupled with the rapid spread of this novel virus. We observe that while cross species adaptation of the virus is associated with hypervariability of specific protein coding regions (including the RDB domain of the spike protein), the more variable genomic regions between extant SARS-CoV-2 episomes correspond with the 3' and 5' UTRs, suggesting that at present viral protein coding genes should not be subjected to different adaptive evolutionary pressures in different viral strains. Although this study can not be conclusive, we believe that the evidence presented here is strongly consistent with the notion that the biased geographic distribution of SARS-CoV-2 isolates should not be associated with adaptive evolution of this novel pathogen.

show abstract

“…On top of these, what are the best therapeutic options we have ready to help cure COVID-19 patients? With 15% of patients suffering from severe disease, hospitals being overwhelmed worldwide and a global mortality rate of 5.7% [1], it goes without saying that new efficacious treatments are immediately needed.…”

Section: Luca Cardonementioning

confidence: 99%